Tarrytown-based pharmaceutical company Regeneron has reported revenues for 2025 of $14.3 billion, an increase of 1% over the revenues for 2024. Revenues for the fourth quarter of 2025 increased 3% over what they were in the fourth quarter of 2024, reaching $3.9 billion. Net income for 2025 was $4.5 billion, compared with $4.4 billion for 2024. In the fourth quarter of 2025, the net income was $845 million compared with $918 for the fourth quarter of 2024.
“Regeneron performed well in 2025, with financial strength driven by our four blockbuster medicines and future growth supported by our exciting late-stage clinical portfolio,” said Leonard S. Schleifer, the company’s president and CEO. “In the fourth quarter, we secured label expansions and new filler solutions for EYLEA HD, further enhancing its commercial potential. Dupixent received new approvals in Japan and Europe and is currently the most widely used innovative branded antibody medicine, with over 1.4 million active patients worldwide. Libtayo also secured additional approvals and continues to be the leading immunotherapy for non-melanoma skin cancers. Our current success is underscored by decades of investment in innovative science and technology, setting us up for exciting data read-outs and potential approvals in 2026 in a broad range of diseases.”
Regeneron reported that it has approximately 45 product candidates in clinical development, including a number of marketed products for which it is investigating additional indications.
Regeneron noted that it plans to invest approximately $2 billion to develop a state-of-the-art bulk manufacturing facility in Saratoga Springs, New York, expected to create 1,000 high-paying jobs and to significantly expand manufacturing capacity.
